Wei Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Sun has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Roy Curtiss
Center for Infectious Disease and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona, USA School of Life Sciences, Arizona State University, Tempe, Arizona, USA
3 shared publications- Jeremy C. Henderson
Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA
1 shared publication Joseph Olinzock
Center for Infectious Disease and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona, USA
1 shared publicationM. Stephen Trent
The Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA
1 shared publicationShandiin Sam
Center for Infectious Disease and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona, USA
1 shared publicationShilpa Sanapala
Center for Infectious Disease and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, Arizona, USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2014
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 82 (10) , 4390-4404
LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague
Here, we constructed aYersinia pseudotuberculosismutant strain with arabinose-dependent regulated and delayed shutoff ofcrpexpression (araCPBADcrp) and replacement of themsbBgene with theEscherichia colimsbBgene to attenuate it. Then, we inserted theasdmutation into this construction to form χ10057 [Δasd-206ΔmsbB868::PmsbBmsbB(EC)ΔPcrp21::TTaraCPBADcrp] for use with a balanced-lethal Asd-positive (Asd+) plasmid to facilitate antigen synthesis. A hybrid protein composed of YopE (amino acids [aa]1 to 138) fused with full-length LcrV (YopENt138-LcrV) was synthesized in χ10057 harboring an Asd+plasmid (pYA5199,yopENt138-lcrV) and could be secreted through a type III secretion system (T3SS)in vitroandin vivo. Animal studies indicated that mice orally immunized with χ10057(pYA5199) developed titers of IgG response to whole-cell lysates ofY. pestis(YpL) and subunit LcrV similar to those seen with χ10057(pYA3332) (χ10057 plus an empty plasmid). However, only immunization of mice with χ10057(pYA5199) resulted in a significant secretory IgA response to LcrV. χ10057(pYA5199) induced a higher level of protection (80% survival) against intranasal (i.n.) challenge with ∼240 median lethal doses (LD50) (2.4 × 104CFU) ofY. pestisKIM6+(pCD1Ap) than χ10057(pYA3332) (40% survival). Splenocytes from mice vaccinated with χ10057(pYA5199) produced significant levels of gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin-17 (IL-17) after restimulation with LcrV and YpL antigens. Our results suggest that it is possible to use an attenuatedY. pseudotuberculosisstrain delivering the LcrV antigen via the T3SS as a potential vaccine candidate against pneumonic plague.
- 1 October 2014
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 82 (10) , 4390-4404
Open AccessLcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague
Here, we constructed aYersinia pseudotuberculosismutant strain with arabinose-dependent regulated and delayed shutoff ofcrpexpression (araCPBADcrp) and replacement of themsbBgene with theEscherichia colimsbBgene to attenuate it. Then, we inserted theasdmutation into this construction to form χ10057 [Δasd-206ΔmsbB868::PmsbBmsbB(EC)ΔPcrp21::TTaraCPBADcrp] for use with a balanced-lethal Asd-positive (Asd+) plasmid to facilitate antigen synthesis. A hybrid protein composed of YopE (amino acids [aa]1 to 138) fused with full-length LcrV (YopENt138-LcrV) was synthesized in χ10057 harboring an Asd+plasmid (pYA5199,yopENt138-lcrV) and could be secreted through a type III secretion system (T3SS)in vitroandin vivo. Animal studies indicated that mice orally immunized with χ10057(pYA5199) developed titers of IgG response to whole-cell lysates ofY. pestis(YpL) and subunit LcrV similar to those seen with χ10057(pYA3332) (χ10057 plus an empty plasmid). However, only immunization of mice with χ10057(pYA5199) resulted in a significant secretory IgA response to LcrV. χ10057(pYA5199) induced a higher level of protection (80% survival) against intranasal (i.n.) challenge with ∼240 median lethal doses (LD50) (2.4 × 104CFU) ofY. pestisKIM6+(pCD1Ap) than χ10057(pYA3332) (40% survival). Splenocytes from mice vaccinated with χ10057(pYA5199) produced significant levels of gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin-17 (IL-17) after restimulation with LcrV and YpL antigens. Our results suggest that it is possible to use an attenuatedY. pseudotuberculosisstrain delivering the LcrV antigen via the T3SS as a potential vaccine candidate against pneumonic plague.
- 31 January 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 14 (10) , 878-886
Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines
The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.
- 31 January 2014
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 14 (10) , 878-886
Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines
The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.
- 1 November 2012
- Published by Elsevier in Microbial Pathogenesis
- Vol. 53 (5-6) , 198-206
Amino acid substitutions in LcrV at putative sites of interaction with toll-like receptor 2 do not affect the virulence of Yersinia pestis
- 1 November 2012
- Published by Elsevier in Microbial Pathogenesis
- Vol. 53 (5-6) , 198-206
Amino acid substitutions in LcrV at putative sites of interaction with toll-like receptor 2 do not affect the virulence of Yersinia pestis